Skip to main content
Premium Trial:

Request an Annual Quote

PredictImmune Expands Licensing Deal With Cambridge Enterprise

NEW YORK – PredictImmune announced today an expansion of a worldwide licensing agreement to allow the UK firm first right of refusal to new technologies from Cambridge Enterprise.

The expanded deal grants PredictImmune right of first refusal to technology allowing for the prediction of disease outcome for systemic lupus erythematosus as a follow-on disease, the Cambridge, UK-based company said. A prior deal between the partners covered technology related to the prediction of disease outcome in relapsing-remitting autoimmune and inflammatory disease, specifically for inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

PredictImmune added that the new terms will allow the company to "evolve" its product line and hasten its products into this new therapeutic space.

Financial and other details of the deal were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.